GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » FCF Yield %

ZyVersa Therapeutics (ZyVersa Therapeutics) FCF Yield % : -214.77 (As of Jun. 09, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, ZyVersa Therapeutics's Trailing 12-Month Free Cash Flow is $-7.91 Mil, and Market Cap is $3.68 Mil. Therefore, ZyVersa Therapeutics's FCF Yield % for today is -214.77%.

The historical rank and industry rank for ZyVersa Therapeutics's FCF Yield % or its related term are showing as below:

ZVSA' s FCF Yield % Range Over the Past 10 Years
Min: -1891.54   Med: 0   Max: 0
Current: -214.77


ZVSA's FCF Yield % is ranked worse than
92.08% of 1554 companies
in the Biotechnology industry
Industry Median: -13.915 vs ZVSA: -214.77

ZyVersa Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.


ZyVersa Therapeutics FCF Yield % Historical Data

The historical data trend for ZyVersa Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZyVersa Therapeutics FCF Yield % Chart

ZyVersa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Yield %
- - -10.48 -239.14

ZyVersa Therapeutics Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -103.24 -28.09 -66.44 -305.69 -241.27

Competitive Comparison of ZyVersa Therapeutics's FCF Yield %

For the Biotechnology subindustry, ZyVersa Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZyVersa Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's FCF Yield % falls into.



ZyVersa Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

ZyVersa Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-8.721 / 3.6468
=-239.14%

ZyVersa Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-3.777 * 4 / 6.26175
=-241.27%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZyVersa Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


ZyVersa Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of ZyVersa Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


ZyVersa Therapeutics (ZyVersa Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Executives
Pablo A. Guzman officer: Chief Medical Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover director, officer: Chief Executive Officer 108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr. officer: Chief Scientific Officer C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe officer: Chief Financial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere officer: Chief Commercial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park director C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd. 10 percent owner 4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones director, officer: Chief Financial Officer C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor director, officer: Chief Executive Officer C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp. 10 percent owner 88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880

ZyVersa Therapeutics (ZyVersa Therapeutics) Headlines

From GuruFocus